Hematologic purpura generally refers to thrombocytopenic purpura, whether the patient can be vaccinated with the new crown vaccine can not be generalized, if in the recovery period, platelet count normal cells can be considered for the new crown vaccine, otherwise not. Thrombocytopenic purpura is a blood disease, is the body’s internal platelet count is relatively low, or platelet function is reduced, resulting in bleeding caused by the patient, and the new crown vaccine is a vaccine to prevent the new crown pneumonia. For patients with thrombocytopenic purpura, individuals who are in the acute exacerbation stage with abnormal bleeding symptoms cannot receive the New Crown vaccine, as this may lead to aggravation of the condition. However, if they are in the recovery phase or have recovered and have a normal platelet count in their body, they can be vaccinated. Thrombocytopenic purpura is usually curable and has no sequelae, so individuals can receive the New Crown vaccine in a timely manner after recovery. If abnormal adverse reactions occur after vaccination, seek professional medical help. Tip: “New coronavirus pneumonia and new coronavirus pneumonia” mentioned in this article have been renamed to “new coronavirus infection” on December 26, 2022, as announced by the National Health Commission.